Clinical trial • Phase I • Oncology|Gastroenterology
Clinical trial in Esophageal cancer
Phase I trial for Esophageal cancer. 15 participants.
Overview
- Trial Therapeutic Area
- Oncology|Gastroenterology
- Trial Disease
- Esophageal cancer
- Trial Stage
- Phase I
- Drug Modality
- Diagnostic agent
Key dates
- Initial CTIS Submission Date
- 05-03-2025
- First CTIS Authorization Date
- 13-06-2025
Trial design
Phase I trial across 3 sites in Netherlands.
- Target Sample Size
- 15
Eligibility
Recruits 15 No vulnerable population selected (isVulnerablePopulationSelected: false)..
- Vulnerable Population
- No vulnerable population selected (isVulnerablePopulationSelected: false).
Recruitment
- Planned Sample Size
- 15
- Recruitment Window Months
- 12
Geography
- Total Number Of Sites
- 3
- Total Number Of Participants
- 15
Netherlands
- Earliest CTIS Part Ii Submission Date
- 23-05-2025
- Latest Decision Or Authorization Date
- 26-02-2026
- Processing Time Days
- 279
- Number Of Sites
- 3
- Number Of Participants
- 15
Sites
- Site Name
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
- Department Name
- Department Otorhinolaryngology, Head and Neck Surgery
- Contact Person Name
- Dominic Robinson
- Contact Person Email
- d.robinson@erasmusmc.nl
- Site Name
- Stichting Martini Ziekenhuis
- Department Name
- Maag-, darm-, leverziekten
- Contact Person Name
- Rina Bijlsma
- Contact Person Email
- r.bijlsma@mzh.nl
- Site Name
- Universitair Medisch Centrum Groningen
- Department Name
- Maag-, darm-, leverziekten
- Contact Person Name
- Wouter Nagengast
- Contact Person Email
- w.b.nagengast@umcg.nl
Sponsor
Primary sponsor
- Full Name
- Universitair Medisch Centrum Groningen
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Netherlands
Related trials
Other published trials that may interest you.
- FERUMOXTRAN-10 for Esophageal cancer
- Colistin sulfate; Tobramycin for Esophageal cancer
- Girentuximab (labelled with Zirconium-89) for Gastroenteropancreatic neuroendocrine neoplasms|Hepatocellular carcinoma|Biliary tract cancer
- DOSTARLIMAB for Resectable colon cancer (pMMR/MSS)
- D,L-LYSINE ACETYLSALICYLATE for Metastatic colorectal cancer|Chemo-resistant metastatic colorectal cancer